Written questions by Blackman.

Whether the Government plans to mandate structured medication reviews for patients receiving long-term sodium valproate, particularly as part of antiepileptic polytherapy.

There are no current plans to mandate Structured Medication Reviews (SMRs) specifically for patients receiving long-term sodium valproate. NHS England has, however, provided substantial funding to expand the number of clinical pharmacists working in primary care networks, with a key part of their role being to undertake SMRs for groups of patients who are most likely to benefit. Whilst treatment with sodium valproate does not, in itself, guarantee an SMR, an SMR might be triggered if a patient meets certain criteria, for example, if they are considered to have complex and problematic polypharmacy or if they are in a care home.

What assessment has been made of the adequacy of the diagnostic time taken and levels of misdiagnosis among individuals harmed by sodium valproate, and its impact on long-term outcomes.

The Independent Medicines and Medical Devices Safety Review, First Do No Harm, identified significant shortcomings in National Health Service care pathways for people harmed by sodium valproate, including fragmented services, limited diagnostic expertise, delays in diagnosis, and inequitable access to multidisciplinary care. NHS England has acknowledged variation in the availability and adequacy of care pathways, the impact of delayed diagnosis and misdiagnosis on long-term outcomes, and the need for improved care coordination for those requiring lifelong support.In response, NHS England has commissioned a Fetal Exposure to Medicines Services Pilot, being delivered by the Newcastle upon Tyne Hospitals NHS Foundation Trust and the Manchester University NHS Foundation Trust. The pilot provides multidisciplinary diagnostic assessment and is informing the development of improved care pathways, including consideration of specialist multidisciplinary services to support earlier diagnosis, better coordination of care, and reduced reliance on emergency care. Initial learning was shared with NHS England in September 2025, with final recommendations expected this summer to inform decisions on any national commissioning, subject to funding.Finally, whilst integrated care boards (ICBs) are the responsible commissioners of the majority of health services, including services related to medically induced disabilities, no specific guidance has been issued to ICBs in relation to supporting individuals with complex, medicine-induced disabilities arising from sodium valproate.

Whether medicine-induced harm from sodium valproate is systematically captured within NHS patient safety, incident and mortality data.

The National Health Service in England operates a comprehensive central database, the Learn From Patient Safety Events (LFPSE) service, which is a national NHS system for the recording and analysis of patient safety events that occur in healthcare. It collates all records of patient safety incidents made by healthcare providers. Where local healthcare providers identify and record incidents related to sodium valproate, that information will be collated by the LFPSE.On mortality data, the Office for National Statistics (ONS) collects and publishes mortality statistics for deaths registered in England and Wales. Deaths in which harm caused by sodium valproate exposure is a contributing factor are not captured as a distinct, searchable category in ONS mortality statistics. Further information on mortality statistics is available on the ONS website, at the following link:https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/methodologies/userguidetomortalitystatisticsjuly2017#:~:text=Mortality%20statistics%20are%20gathered%20using,data%20for%20the%20previous%20period

Whether conditions arising from sodium valproate exposure are consistently recognised and coded within NHS diagnostic systems.

The National Health Service in England collects data on patients suffering adverse effects of medication and on drug poisoning. While adverse conditions arising from sodium valproate would be captured in this data, the data does not go to the level to identify sodium valproate and is not aligned to coding within NHS diagnostic systems.

What steps are being taken in response to inaccuracies, omissions and loss of NHS medical records relating to historic sodium valproate prescribing.

Affected patients who feel there are inaccuracies or omissions in their medical record can ask for their records to be amended. NHS England’s guidance on amending patient and service user records is available at the following link:https://transform.england.nhs.uk/information-governance/guidance/amending-patient-and-service-user-records/Where patients are not satisfied with the response to their request, they can make a complaint to the Information Commissioner’s Office.

What steps he is taking to provide emergency day-to-day funding to hospices; and whether he will commit to releasing (a) £100 million in emergency funding now and (b) a further £100 million in April 2026 to stabilise hospice services and protect patient care.

Children and young people’s hospices have received £26 million of revenue funding for 2025/26 and we are also providing approximately £80 million of revenue funding for children and young people’s hospices over the next three financial years, 2026/27 to 2028/29, giving them stability to plan ahead and focus on what matters most, caring for their patients. In December 2024, we announced that we were providing £100 million of capital funding for eligible adult and children’s hospices in England. This was split across two financial years, with hospices receiving £25 million to spend in 2024/25 and £75 million to spend in 2025/26. We are pleased to say that we can now confirm we are providing a further £25 million in capital funding for hospices to spend in 2025/26. We are in a challenging fiscal position across the board. At this time, we are not in a position to offer any additional funding beyond that outlined above. However, we are supporting the hospice sector in other ways. The Government is developing a Palliative Care and End of Life Care Modern Service Framework (MSF) for England. As part of the MSF, we will consider contracting and commissioning arrangements. We recognise that there is currently a mix of contracting models in the hospice sector. By supporting integrated care boards to commission more strategically, we can move away from grant and block contract models. In the long term, this will aid sustainability and help hospices’ ability to plan ahead.

When he plans to update the Wave 1 Part IX categorisation published by the NHS Business Services Authority: and what mechanisms are in place for the Drug Tariff Committee and suppliers to provide input into revisions.

The final draft, version 1.2, of the Part IX Drug Tariff (Med Tech in the community) wave one categorisation was developed in collaboration with an Expert Reference Group and updated in line with stakeholder feedback over four iterations. The final version was published in October 2025, and can be found on the NHS Business Services Authority Website at the following link:https://www.nhsbsa.nhs.uk/manufacturers-and-suppliers/drug-tariff-part-ix-informationThe Department is currently recruiting Independent Assessment Panels (IAPs) for wave one and has agreed to ask them to review late feedback received from a company on the eye drops category. This is due to take place in February 2026.This will not require further input from industry as it has already been circulated for comment by them. The Department has offered to review Drug Tariff Committee feedback regarding the categorisation of medical devices that fall into waves two to four.The categorisation for waves two and three is currently being reviewed, and the Department expects to share the updated versions in early 2026, well in advance of the projected launch of waves two and three in 2027 and 2028 respectively. There are no confirmed plans for reviewing wave four at this time. The earliest launch would be in January 2029. All dates are subject to the outcome of the review of wave one.The Department recognises that the categorisation is not stagnant and may need further amendments as medical devices continue to evolve. Companies can suggest further amendments when they apply to Part IX of the Drug Tariff or through the Drug Tariff Committee.

When he expects to complete his review of stakeholder feedback submitted in April 2025 on the Part IX re-categorisation process for Waves 1 to 4, and when updates will be shared with the Drug Tariff Committee and Forum members.

The final draft, version 1.2, of the Part IX Drug Tariff (Med Tech in the community) wave one categorisation was developed in collaboration with an Expert Reference Group and updated in line with stakeholder feedback over four iterations. The final version was published in October 2025, and can be found on the NHS Business Services Authority Website at the following link:https://www.nhsbsa.nhs.uk/manufacturers-and-suppliers/drug-tariff-part-ix-informationThe Department is currently recruiting Independent Assessment Panels (IAPs) for wave one and has agreed to ask them to review late feedback received from a company on the eye drops category. This is due to take place in February 2026.This will not require further input from industry as it has already been circulated for comment by them. The Department has offered to review Drug Tariff Committee feedback regarding the categorisation of medical devices that fall into waves two to four.The categorisation for waves two and three is currently being reviewed, and the Department expects to share the updated versions in early 2026, well in advance of the projected launch of waves two and three in 2027 and 2028 respectively. There are no confirmed plans for reviewing wave four at this time. The earliest launch would be in January 2029. All dates are subject to the outcome of the review of wave one.The Department recognises that the categorisation is not stagnant and may need further amendments as medical devices continue to evolve. Companies can suggest further amendments when they apply to Part IX of the Drug Tariff or through the Drug Tariff Committee.

What guidance he plans to issue to local Trading Standards teams on identifying high-capacity non-compliant disposable vapes under the powers created by the Tobacco and Vapes Bill.

It has been illegal for businesses to sell or supply single-use vapes since 1 June 2025. The Government is investing £10 million of new funding in Trading Standards in 2025/26, to support the enforcement of illicit and underage tobacco and vape sales. As part of this package, we have provided training to over 760 Trading Standards officers on the single-use vapes ban, ensuring they have a strong understanding of the regulations and are confident in enforcing them.Through this programme, we are also funding the Vaping Expert Panel, which provides guidance to Trading Standards officers on vaping products to support the consistent enforcement of regulations. The panel has published 20 pieces of guidance, and Trading Standards officers are able to contact the panel if they would like further clarification or advice.

Whether he will publish a timetable for introducing product-verification checks under the new vape registration scheme, in order to assist Trading Standards in identifying non-compliant high-capacity devices at point of sale.

Powers in the Tobacco and Vapes Bill allow us to establish a new product registration scheme for tobacco, vaping, and nicotine products. On 8 October 2025, we published a call for evidence on a number of topics related to tobacco, vaping, and nicotine products. This includes the proposal to introduce a new product registration scheme.In the call for evidence, we are seeking information on how best to implement the registration scheme. The evidence gathered will inform development of policy and a subsequent consultation next year.

What assessment he has made of the level of resources required by the MHRA to implement the new registration and testing regime for vaping products established under the Tobacco and Vapes Bill.

No assessment has yet been made as the registration scheme is still in the early stages of policy development. On 8 October 2025, we published a call for evidence on a number of topics related to tobacco, vaping and nicotine products, including the proposal to introduce a new product registration scheme. However, given the nature of vaping products, which are not healthcare products, officials from the Department and the Office for Product Safety and Standards (OPSS) are considering whether OPSS would be better placed to oversee the future register. The Department and the Medicines and Healthcare products Regulatory Agency will continue to be responsible for the current notification systems until further notice. Powers in the bill will allow us to charge a fee for the ongoing and continuous registration of products. Exact details on fees, as well as the future registration scheme, will be subject to future consultation.

Whether the forthcoming testing regime for vaping products will require imported liquids to undergo the same emissions and ingredient analysis as UK-made liquids before being placed on the UK market.

Powers in the Tobacco and Vapes Bill allow us to establish a new product registration scheme for tobacco, vaping, and nicotine products, including testing requirements.On 8 October 2025, we published a call for evidence on a number of topics related to tobacco, vaping, and nicotine products, including the proposal to introduce a new product registration scheme. The evidence gathered will inform development of policy and a subsequent consultation next year.Any new testing requirements introduced following consultation will apply to products produced in the United Kingdom and those imported into the UK.

What assessment his Department has made of the efficacy of hospitals delivering specialist multi-disciplinary teams for patients experiencing homelessness.

The Department published guidance in 2024 called Discharging people at risk of or experiencing homelessness to support the care transfer hub, which is available at the following link:https://www.gov.uk/government/publications/discharging-people-at-risk-of-or-experiencing-homelessness/discharging-people-at-risk-of-or-experiencing-homelessnessThis guidance recognises the necessity for multi-disciplinary teams. It recommends that dedicated housing options officers are embedded within the care transfer hub and advises hospitals treating over 200 homeless patients a year to offer access to a specialist multi-disciplinary homeless discharge team.Some areas of the country have introduced High Intensity Use Services to proactively meet the needs of the most frequent attenders of the local accident and emergency, a significant portion of whom are experiencing homelessness. These services include multi-disciplinary teams that are helping to address health inequalities faced by this cohort while alleviating pressure on urgent and emergency care pathway,

Whether his Department will consider enabling electronic prescribing for cannabis-based products for medicinal use, in line with other controlled drugs.

Rules around the electronic prescribing of cannabis-based medicines are no different to other drugs regulated in Schedule 2 to 5 of the Misuse of Drugs Regulations 2001.In England, the NHS Electronic Prescription Service enables the electronic transmission of prescriptions for Schedule 2 to 5 controlled drugs. As part of the robust system of governance and restrictions around the most addictive and harmful drugs, all private healthcare provider prescriptions for Schedule 2 and 3 controlled drugs cannot be transmitted by electronic means and must be issued on a paper FP10PCD prescription form. All paper copies of private prescriptions of Schedule 2 and 3 controlled drugs must be submitted to the NHS Business Services Authority. NHS England’s Controlled Drug Accountable Officers have a statutory duty to monitor the management and use of controlled drugs in the National Health Service and private healthcare.The Medicines and Healthcare products Regulatory Agency (MHRA) does not provide guidance on the use of medicinal cannabis. The MHRA provides guidance on manufacturing, importing, distributing, and supplying unlicensed medicines, which includes cannabis-based products for medicinal use in humans.Current guidelines on the prescribing and use of cannabis-based medicinal products, reference code NG144, is published on the National Institute for Health and Care Excellence website, which is available at the following link:https://www.nice.org.uk/

What steps his Department is taking in collaboration with the Medicines and Healthcare products Regulatory Agency to ensure that clinical guidelines relating to cannabis-based medicinal products are consistent, evidence-based, and provide clarity to prescribers.

Rules around the electronic prescribing of cannabis-based medicines are no different to other drugs regulated in Schedule 2 to 5 of the Misuse of Drugs Regulations 2001.In England, the NHS Electronic Prescription Service enables the electronic transmission of prescriptions for Schedule 2 to 5 controlled drugs. As part of the robust system of governance and restrictions around the most addictive and harmful drugs, all private healthcare provider prescriptions for Schedule 2 and 3 controlled drugs cannot be transmitted by electronic means and must be issued on a paper FP10PCD prescription form. All paper copies of private prescriptions of Schedule 2 and 3 controlled drugs must be submitted to the NHS Business Services Authority. NHS England’s Controlled Drug Accountable Officers have a statutory duty to monitor the management and use of controlled drugs in the National Health Service and private healthcare.The Medicines and Healthcare products Regulatory Agency (MHRA) does not provide guidance on the use of medicinal cannabis. The MHRA provides guidance on manufacturing, importing, distributing, and supplying unlicensed medicines, which includes cannabis-based products for medicinal use in humans.Current guidelines on the prescribing and use of cannabis-based medicinal products, reference code NG144, is published on the National Institute for Health and Care Excellence website, which is available at the following link:https://www.nice.org.uk/

What steps he plans to take to help ensure that imported vaping liquids are subject to the same (a) safety and (b) nicotine-level testing as those produced by UK-regulated manufacturers.

Powers in the Tobacco and Vapes Bill allow us to establish a new registration scheme for tobacco, vaping, and nicotine products. Under this scheme, manufacturers of vaping liquids, as well as other products, would be required to provide information verifying the product’s safety and compliance with our product rules. Alongside this, the bill provides powers to establish a more rigorous testing regime for these products. These rules will apply to products produced in the United Kingdom and those imported for sale into the UK.There are questions on both the registration and testing of products in the recently published Call for Evidence. In this, we are seeking information on how best to implement the registration scheme, as well as elements such as testing standards. The evidence gathered will inform development of policy and a subsequent consultation. Further information on the Call for Evidence is available at the following link:https://www.gov.uk/government/calls-for-evidence/tobacco-and-vapes-evidence-to-support-legislationThe future registration scheme will play an important part in enforcing our rules on product requirements. It will ensure consumer safety and improve retailer confidence in the products they are selling.

What steps he plans to take to ensure that the proposed pre-filled pod ban amendment in the Tobacco and Vapes Bill prevents the sale of non-compliant imported liquids to under-age users.

The Tobacco and Vapes Bill does not include any measures which would ban pre-filled vape pods, and we have no plans to amend the Bill or bring forward secondary legislation to this effect. An amendment put forward by Earl Russell that proposes to ban pre-filled pods was debated and subsequently withdrawn during the second committee session for the Tobacco and Vapes Bill in the House of Lords.The Bill will enable the introduction of a new registration scheme for all tobacco, vaping and nicotine products, which will ensure that only compliant imported e-liquids are available for sale in the United Kingdom. The Bill also ensures that all vaping products, including pre-filled pods, will fall under the same age of sale of 18 years old, and new fixed penalty notices will support Trading Standards in taking swift action in relation to underage sales.

Whether he has made an estimate of the number of illegal vape imports that do not comply with the Medicines and Healthcare products Regulatory Agency’s notification and testing regime which have entered the UK market in the most recent period for which data is available.

Before a nicotine vape can be placed on the United Kingdom consumer market, producers or manufacturers must first submit a notification to the Medicines and Healthcare products Regulatory Agency (MHRA), in accordance with the Tobacco and Related Products Regulations 2016. If the notification data is compliant, the notification will be published on the MHRA portal.However, under the current system, there is no requirement to check a product against its notification. There is also no current testing regime for nicotine vapes – this is done on an ad hoc basis where there is concern a product does not meet regulations. Therefore, no estimate has been made.Powers in the Tobacco and Vapes Bill will enable us to establish a new registration scheme and more rigorous testing regime for tobacco, vaping and nicotine products.Enforcement agencies continue to take action to ensure that illegal vapes do not reach consumers. In 2024/25, over one million illicit vapes were seized inland, and over 1.2 million illicit vapes were detained at ports by Trading Standards in England.

What steps is the Department taking to promote earlier detection, ensure dentists, GPs and other frontline health professionals are trained to identify early warning signs, and improve timely diagnosis and referral for treatment in relation to mouth cancer.

We know that more needs to be done to improve outcomes for patients with mouth cancer. Our forthcoming National Cancer Plan will have patients at its heart and will include further details on how we will speed up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately drive up this country’s cancer survival rates.To support earlier and faster cancer diagnosis, we are now delivering additional checks, tests, and scans at 170 community diagnostic centres.Additionally, to help increase early detection of cancer, the Government has recently launched Jess’s Rule, an initiative that asks general practitioners (GPs) to think again if, after three appointments, they have been unable to diagnose a patient, or their symptoms have escalated.We are also investing an additional £889 million in GPs, bringing total spend on the GP Contract to £13.2 billion in 2025/26. This will help to ensure that we have a well-trained and well-equipped primary care service that can take the time to provide quality care to patients around the country.Dentists and other dental professionals, including hygienists, routinely check the soft tissues of a patient’s mouth for signs of cancer during dental visits and, as part of the check-up, will make an assessment and record an individual’s oral cancer risk. Dentists will prioritise patients at a higher risk of oral cancer for more frequent recall and review in line with National Institute for Health and Care Excellence guidance.

Whether his Department plans to update impact assessments for Part IX Drug Tariff reform in the context of methodological changes following the introduction of interchangeable size bandings.

The Impact Assessment was shared at the consultation stage which took place between October 2023 and January 2024. It was subsequently updated to reflect the industry feedback received throughout the process, with the final version being released in August 2024. Further detail has since been provided on the assessment of wound care in line with the existing principles that products will be grouped into clinically comparable clusters.Therefore, when NHS Prescription Services apply these principles to wound care dressings, it is expected that dressings will be grouped into different sizes, reflecting the fact that different sized dressings meet different clinical needs. The programme is now in the implementation stage, and the impacts will be reviewed through the agreed evaluation process for Wave 1, in collaboration with industry.